Xcellerex Raises $31 Million

Xcellerex Inc. has raised $31 million in Series C funding. VantagePoint Venture Partners led the deal, and was joined by return backers Kleiner Perkins Caufield and Byers and SCG Investments. The Marlborough, Mass.-based company has developed a manufacturing system and bioreactors for the production of biomolecules, including biotherapeutics and vaccines. It previously had raised around $14 million. www.xcellerex.com